Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: single photon emission computed tomography Clear all

Conditions: Alzheimer Disease
Interventions: [123I]AV94; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 50 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Alzheimer Disease
Interventions: SPECT scan; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 50 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Leukemia, Lymphoma
Interventions: Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions: SPECT/CT perfusion imaging, PET/CT perfusion imaging; Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Parkinson Disease
Interventions: B-CIT and SPECT imaging; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 30 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Refractory Myelodysplastic Syndrome
Interventions: Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography; Radiation · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Embolism
Interventions: Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging; Drug
Lead sponsor: Cyclomedica Australia PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Myeloma Before MV-NIS Treatment, Endometrial Cancer Before VSV-hINF-NIS Treatment
Interventions: 18F-TFB-PET; Combination Product
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Thromboembolisms, Pulmonary Embolism
Interventions: 4DCT and SPECT/CT, 4DCT with BiPAP and SPECT/CT, 4DCT with CTA in suspected PE; Device
Lead sponsor: Thomas Guerrero; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Lung Carcinoma, Malignant Neoplasm
Interventions: SPECT/CT, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m DTPA; Diagnostic Test · Procedure · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Neuroendocrine Carcinoma
Interventions: 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan, MRI; Drug · Diagnostic Test
Lead sponsor: Radio Isotope Therapy of America; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure, Coronary Artery Disease, Ischemic Cardiomyopathy
Interventions: Advanced cardiac imaging, Standard Cardiac Imaging; Other
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinsonian Syndrome
Interventions: [123I]ß CIT and SPECT imaging; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 22 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
Interventions: [203Pb]VMT-α-NET, SPECT/CT; Drug · Device
Lead sponsor: Yusuf Menda; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Interventions: Angiogram, Biospecimen Collection, Computed Tomography, Radioembolization, Single Photon Emission Computed Tomography, Survey Administration, Yttrium Y 90 Glass Microspheres; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Los Angeles, California • Aurora, Colorado

Conditions: Coronary Artery Disease
Interventions: SPECT imaging; Radiation
Lead sponsor: Prem Soman; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: Antigravity treadmill (Alter-G), Conventional treadmill/regadenoson; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Arthritis, Rheumatoid
Interventions: Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View; Drug · Procedure
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Breast Cancer, Lymphedema
Interventions: screening questionnaire administration, computed tomography, lymphoscintigraphy, single photon emission computed tomography, intensity-modulated radiation therapy, technetium Tc 99m sulfur colloid; Other · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimers Disease
Interventions: [123I] AV 39; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
Interventions: Active Breathing Coordinator; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Interventions: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography; Radiation · Drug · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions: [123I]CLINDE; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 30 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Thyroid Gland Follicular Carcinoma
Interventions: Computed Tomography, Iodine I-123, Planar Imaging, Single Photon Emission Computed Tomography; Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Simultaneous Assessment of FFR and SPECT

Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery